Spondyloarthritis

Clinical Immunology

Volumn , Issue , 2008, Pages 837-857

  Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650592298     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04404-2.10057-0     Document Type: Chapter

References (40)

1. Monnet D., Breban M., Hudry C., et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004, 111:802-809.
2. Bergtfeldt L. HLA-B27 associated cardiac disease. Ann Intern Med 1997, 127:621-629.
3. Dougados M., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227.
4. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
5. Rudwaleit M., van der Heijde D., Khan M.A., et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004, 63:535-543.
6. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
7. Braun J., Kingsley G., van der Heijde D., et al. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000, 27:2185-2192.
8. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
9. Maurer K. Basic data on arthritis: knee, hip and sacroiliac joints in adults ages 25-74 years, United States, 1971-1975. Vital Health Stat 1979, 11:213.
10. Sieper J., Rudwaleit M., Khan M.A., et al. Concepts and epidemiology of spondyloarthriits. Best Pract Res Clin Rheumatol 2006, 20:401-417.
11. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
12. Brown M.A., Kennedy L.G., MacGregor A.J., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997, 40:1823-1828.
13. Reveille J.D., Arnett F.C. Spondyloarthritis: update on pathogenesis and treatment. Am J Med 2005, 118:592-603.
14. Reveille J.D. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol 2006, 18:332-341.
15. Smith J.A., Marker-Hermann E., Colbert R.A. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol 2006, 20:571-591.
16. Carter K.W., Pluzhnikov A., Timms A.E., et al. Meta-analysis of three whole genome linkage scans for ankylosing spondylitis. Rheumatol (Oxf) 2006, in press.
17. Elder J.T. PSORS1. Linking genetics and epidemiology. J Invest Dermatol 2006, 126:1205-1206.
18. Mielants H., De Keyser F., Baeten D., et al. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 2005, 7:188-194.
19. Ritchlin C.T. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005, 17:406-412.
20. McGonagle D., Gibbon W., Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998, 352:1137-1140.
21. Sweeney S., Gupta R., Taylor G., et al. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001, 28:1862-1866.
22. Mitra D., Elvins D.M., Speden D.J., et al. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatol (Oxf) 2000, 39:85-89.
23. Maillefert J.F., Aho L.S., El Maghraoui A., et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001, 12:605-609.
24. Lee W., Reveille J.D., Davis J.C., et al. Are there gender differences in the severity of ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 2006 Nov 24, [Epub ahead of print].
25. Burgos Vargas R. Juvenile onset spondyloarthritides. Rheum Dis Clin North Am 2002, 28:541-560.
26. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
27. van der Heijde D., Landewe S., van der Linden S. How should treatment effect on spinal radiographic progression be measurred?. Arthriits Rheum 2005, 52:1979-1985.
28. Zeidler H., Brandt J., Schnarr S. Undifferentiated spondyloarthritis. Ankylosing Spondylitis and the Spondyloarthropathies 2006, 75-93. Elsevier, Philadelphia, PA. M.H. Weisman, J.D. Reveille, D. van der Heijde (Eds.).
29. Chen C.H., Lin K.C., Yu D.T., et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatol (Oxf) 2006, 45:414-420.
30. Ward M.M., Weisman M.H., Davis J.C., et al. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005, 53:710-717.
31. Maksymowych W.P., Inman R.D., Salonen D., et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005, 53:703-709.
32. Sairanen E., Paronen I., Mahonen H. Reiter's syndrome: a follow-up study. Acta Med Scand 1969, 185:57-63.
33. Wanders A., van der Heijde D., Landewe R., et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1761.
34. Clegg D.O., Reda D.J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325-2329.
35. Gorman J., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002, 346:1349-1356.
36. Laasila K., Laasonen L., Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003, 62:655-658.
37. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
38. Van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
39. Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
40. Van Royen B.J., De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis 1999, 58:399-406.